About Acrivon Therapeutics
Acrivon Therapeutics (NASDAQ:ACRV) is a pioneering force in the realm of precision oncology, focusing on the development of advanced treatments tailored to combat cancer more effectively. The company zeroes in on unlocking personalized therapy options by leveraging its proprietary platform to predict patient responses to its investigational drugs. This approach not only aims to enhance the success rates of cancer treatments but also seeks to significantly improve patient outcomes by aligning therapies with individual genetic profiles. Acrivon Therapeutics is dedicated to pushing the boundaries of medical science, with ongoing projects aimed at addressing various forms of cancer. Its objectives encompass advancing its pipeline of targeted therapies through clinical trials, with the ultimate goal of achieving regulatory approval and bringing novel, effective cancer treatments to the market.
Snapshot
Operations
Products and/or services of Acrivon Therapeutics
- Development of precision oncology medicines utilizing proprietary Predictive Precision Proteomics platform to match patients with effective treatments.
- Advancement of ACR-368, a targeted therapy aimed at specific cancer mutations, into clinical trials.
- Collaboration on biomarker discovery projects to enhance personalization in cancer treatment, leveraging advanced proteomics and computational technologies.
- Provision of comprehensive molecular diagnostic services to identify actionable mutations in cancer patients.
- Research on novel drug targets for hard-to-treat cancers, based on in-depth tumor biology understanding.
- Partnership programs with pharmaceutical companies to co-develop targeted therapies for various cancer types.
Acrivon Therapeutics executive team
- Dr. Peter Blume-Jensen M.D., Ph.D.Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
- Ms. Kristina Masson M.B.A., Ph.D.Co-Founder, Executive VP of Business Operations, Site Head, Treasurer & Director
- Dr. Eric J. Devroe Ph.D.Chief Operating Officer
- Dr. Adam D. Levy M.B.A., Ph.D.CFO & Principal Financial Officer
- Ms. Katharine Peterson CPAVice President of Finance & Accounting
- Mr. Bruce CloseVice President of Quality & Compliance
- Ms. Mary-Alice Miller J.D.Chief Legal Officer & Corporate Secretary
- Dr. Erick Gamelin M.D., Ph.D.Chief Development Officer
- Dr. Jesper V. Olsen Ph.D.Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board
- Mr. Joon Jung Ph.D.VP & Head of Data Science